Dyne Therapeutics' stock dropped 16% following Novartis' failure in a DM1 clinical trial, which increased concerns about the effectiveness of RNA-targeting therapies for muscle diseases. This setback challenges the potential of Dyne's lead drug, z-rostudirsen, especially regarding its long-term functional benefits despite likely FDA approval. Dyne remains financially strong with nearly $900 million in cash and a $3.9 billion enterprise value, supporting its ongoing Phase 3 trials. However, investor confidence has waned, applying a higher risk discount to Dyne's pipeline prospects.
NANO Nuclear Energy has appointed Marilyn Diaz as Director of Fuel Facilities Operations. Diaz brings over 17 years of experience from the U.S. Nuclear Regulatory Commission, where she held leadership roles in reactor regulation and nuclear fuel lice...
Strive, Inc. has overtaken Metaplanet in market capitalization despite holding about 24,531 BTC compared to Metaplanet's 43,000 BTC. Strive's valuation rose to $2.5-$3 billion, fueled by aggressive Bitcoin purchases and financing through SATA perpetu...
Bitcoin is trading near $78,700 after multiple failed attempts to surpass the $79,500 resistance level, leaving the market uncertain between pushing toward $82,000 or falling back to support levels around $70,500 and lower. Traders are cautious ahead...
TKO Group Holdings is rated a 'Buy' due to its valuable media rights and franchise assets from UFC and WWE, which allow scalable revenue through sponsorships, licensing, and archives with low extra costs. The company aims for $5.8 billion in revenue ...
US Bank successfully completed a live pilot of its USBDC stablecoin, enabling real-time cross-border payments between its North American and European branches on the Stellar blockchain. This pilot tested the full stablecoin lifecycle and integrated w...
